Fundamental Analysis of Haemonetics Corporation - Growth / Value Index
HAE - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.160
Book Value in last 3 years is trending up
Price to Book Ratio of 5.51 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 41.91 | 41.91 | 0.0127 % | |
| Price to Book | 5.37 | 5.13 | -13.18 % | 5.13 |
| Price to Sales | 3.76 | 3.76 | -9.04 % | |
| Enterprise Value to EBITDA Multiple | 21.35 | 14.89 | -30.18 % |
HAE - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 9.0
Company Earning excess return
Reasonable Dividend Yield of 3.19 %
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 15.07
Good Return on Equity of 14.38% is achieved by the company
Low Earning Yield of 2.61 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 12.82 | 12.25 | -13.20 % | 2.12 |
| Return On Asset | 5.70 | 5.35 | -10.23 % | 0.928 |
| Net Profit Margin | 8.98 | 8.98 | -9.06 % | 5.93 |
| Operating Profit Margin | 12.91 | 14.54 | 8.91 % | 9.92 |
| EBITDA Margin | 16.82 | 24.41 | 14.43 % | 17.97 |
Highlights
| Market Cap | 4868.36 M |
| Enterprise Value | 4699.78 M |
| Price/Book TTM | 5.37 |
| Outstanding Share | 50786.10 K |
| Float/ Outstanding Share | 99.19% |
| Dividend Yield | 3.19 % |
Share Holding
Guru Numbers
| Price/Graham No | 3.09 |
| Peter Lynch Ratio | 0.0005 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 3.25 |
| Sloan Ratio | -0.0292 |
| Peter Lynch Fair Value | 24.29 |
HAE - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
YoY Net Margin Jump by 126.11%
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 1309.06 M | 12.01 % | 2.09 % |
| Gross Profit | 697666 K | 9.99 % | 2.34 % |
| EBITDA | 220171 K | 28.18 % | 11.23 % |
| Net Profit | 117558 K | 1.87 % | 34.81 % |
| EPS | 2.29 | 0.0127 % | NA |
HAE - Stability Highlights
Stability Analysis
Altman Z Score of 3.95 suggests good Stability
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0107 | -98.86 % | 0.0107 |
| Cash Ratio | 0.595 | -47.31 % | |
| Quick Ratio | 1.50 | -25.80 % | 1.50 |
| Shareholders Equity | 43.72 | 3.42 % | |
| Debt to EBITDA | 0.0320 | -98.96 % |
Historical Valuation Ratios of Haemonetics Corporation
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Haemonetics Corporation
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Haemonetics Corporation
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Haemonetics Corporation
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)